A detailed history of Quadrant Capital Group LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 205 shares of ACAD stock, worth $3,538. This represents 0.0% of its overall portfolio holdings.

Number of Shares
205
Holding current value
$3,538
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$15.14 - $19.14 $3,103 - $3,923
205 New
205 $3,000
Q3 2022

Nov 10, 2022

BUY
$14.11 - $18.27 $5,206 - $6,741
369 Added 559.09%
435 $7,000
Q2 2022

Aug 09, 2022

SELL
$13.01 - $27.22 $572 - $1,197
-44 Reduced 40.0%
66 $1,000
Q1 2022

May 06, 2022

SELL
$20.94 - $27.5 $1,654 - $2,172
-79 Reduced 41.8%
110 $2,000
Q4 2021

Feb 01, 2022

BUY
$16.79 - $27.09 $789 - $1,273
47 Added 33.1%
189 $4,000
Q3 2021

Nov 12, 2021

SELL
$15.78 - $24.77 $6,596 - $10,353
-418 Reduced 74.64%
142 $2,000
Q2 2021

Aug 09, 2021

BUY
$19.4 - $27.42 $8,283 - $11,708
427 Added 321.05%
560 $14,000
Q1 2021

May 12, 2021

BUY
$25.02 - $54.99 $675 - $1,484
27 Added 25.47%
133 $3,000
Q4 2020

Feb 16, 2021

BUY
$41.04 - $56.79 $2,667 - $3,691
65 Added 158.54%
106 $6,000
Q3 2020

Nov 13, 2020

BUY
$36.42 - $57.0 $1,493 - $2,337
41 New
41 $2,000
Q2 2020

Aug 13, 2020

SELL
$39.26 - $52.73 $38,003 - $51,042
-968 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $5,728 - $8,483
-181 Reduced 15.75%
968 $41,000
Q4 2019

Feb 03, 2020

BUY
$36.21 - $51.4 $6,554 - $9,303
181 Added 18.7%
1,149 $48,000
Q2 2019

Jul 24, 2019

BUY
$23.32 - $28.12 $22,573 - $27,220
968 New
968 $25,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.79B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.